Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jan;13(1):21-24.
doi: 10.1200/JOP.2016.018846. Epub 2017 Jan 3.

Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion

Phuoc T Tran  1 , Emmanuel S Antonarakis  1
Affiliations
Comment

Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion

Phuoc T Tran et al. J Oncol Pract. 2017 Jan.
No abstract available

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
The oligometastatic disease state. The spectrum of malignant disease is represented by blue ovals for primary prostate cancer and red circles for macroscopic metastases. Patients are considered in relation to the putative benefits of local versus systemic therapies. Men in the oligometastatic disease state may benefit from both systemic therapy and local therapies.
See this image and copyright information in PMC

Comment on

References

    1. Rubin P, Green J. Springfield, IL, C.C: Thomas; 1968. Solitary Metastases.
    1. Palma DA, Salama JK, Lo SS, et al. The oligometastatic state: Separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11:549–557. - PubMed
    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10. - PubMed
    1. Uppal A, Wightman SC, Mallon S, et al. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015;6:3540–3552. - PMC - PubMed
    1. Gomez DR, Blumenschein GR, Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 10.1016/S1470-2045(16)30532-0 [epub ahead of print on October 24, 2016] - DOI - PMC - PubMed

Publication types

LinkOut - more resources